Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrially encoded tRNA-Ser (UCN) 1, abbreviated as MT-TS1, is a small mitochondrial transfer RNA molecule that enables the incorporation of the amino acid serine (coded by the UCN anticodon) into proteins during mitochondrial translation. It is critical for correct mitochondrial protein synthesis, particularly for proteins involved in oxidative phosphorylation, which is central to cellular energy production. Pathogenic mutations in MT-TS1 disrupt normal mitochondrial protein synthesis and cause diverse clinical syndromes, mainly affecting organs with high energy demand such as muscle (myopathy, exercise intolerance, myoclonic epilepsy) and sensory tissues (hearing loss, keratoderma)[1][2][6][8]. MT-TS1 itself is not a drug target, but genetic testing for MT-TS1 mutations is used to aid diagnosis in mitochondrial diseases[1][6][8].
Not applicable. There are no drug mechanisms associated with this tRNA; disease processes result from genetic mutations affecting its function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded tRNA-Ser (UCN) 1 (MT-TS1).